A carregar...
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Programmed death receptor-1/ligand 1 (PD-1/L1) antibodies can induce durable remissions in malignancies. However, response rates are only ~10–20% in unselected patients versus ~50% in microsatellite instability-high (MSI-high) tumors, probably related to high tumor mutational burden (TMB). Pembroliz...
Na minha lista:
| Publicado no: | Cancer Immunol Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6774837/ https://ncbi.nlm.nih.gov/pubmed/31405947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0149 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|